These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10638666)

  • 21. Postinjury suppression of human neutrophil cytokine production results from the stabilization of inhibitory kappaB.
    Zallen G; Moore EE; Johnson JL; Tamura DY; Shames B; Biffl WL; Silliman CC
    Shock; 1999 Feb; 11(2):77-81. PubMed ID: 10030791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of cytosolic phospholipase A2 and secretory phospholipase A2 in arachidonic acid release from human neutrophils.
    Marshall J; Krump E; Lindsay T; Downey G; Ford DA; Zhu P; Walker P; Rubin B
    J Immunol; 2000 Feb; 164(4):2084-91. PubMed ID: 10657662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucocorticoids suppress basal (but not interleukin-1-supported) ovarian phospholipase A2 activity: evidence for glucocorticoid receptor-mediated regulation.
    Kol S; Ben-Shlomo I; Payne DW; Ando M; Rohan RM; Adashi EY
    Mol Cell Endocrinol; 1998 Feb; 137(2):117-25. PubMed ID: 9605513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
    Pruzanski W; Stefanski E; Vadas P; Ramamurthy NS
    Biochem Pharmacol; 1997 Jun; 53(12):1901-7. PubMed ID: 9256165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors.
    Pruzanski W; Stefanski E; Vadas P; Kennedy BP; van den Bosch H
    Biochim Biophys Acta; 1998 May; 1403(1):47-56. PubMed ID: 9622592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor.
    Morioka Y; Saiga A; Yokota Y; Suzuki N; Ikeda M; Ono T; Nakano K; Fujii N; Ishizaki J; Arita H; Hanasaki K
    Arch Biochem Biophys; 2000 Sep; 381(1):31-42. PubMed ID: 11019817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms.
    Yokota Y; Hanasaki K; Ono T; Nakazato H; Kobayashi T; Arita H
    Biochim Biophys Acta; 1999 May; 1438(2):213-22. PubMed ID: 10320804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial assessment of biochemical changes in irradiated red blood cells.
    Patidar GK; Joshi A; Marwaha N; Prasad R; Malhotra P; Sharma RR; Dhawan HK
    Transfus Apher Sci; 2014 Jun; 50(3):479-87. PubMed ID: 24594298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy with interleukin-2 induces the systemic release of phospholipase-A2.
    Wolbink GJ; Schalkwijk C; Baars JW; Wagstaff J; van den Bosch H; Hack CE
    Cancer Immunol Immunother; 1995 Nov; 41(5):287-92. PubMed ID: 8536274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rat ovarian phospholipase A2 system: gene expression, cellular localization, activity characterization, and interleukin-1 dependence.
    Kol S; Ruutiainen-Altman K; Ben-Shlomo I; Payne DW; Ando M; Adashi EY
    Endocrinology; 1997 Jan; 138(1):322-31. PubMed ID: 8977420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms that account for the selective release of arachidonic acid from intact cells by secretory phospholipase A2.
    Fonteh AN; Samet JM; Surette M; Reed W; Chilton FH
    Biochim Biophys Acta; 1998 Aug; 1393(2-3):253-66. PubMed ID: 9748613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes.
    Triggiani M; Granata F; Oriente A; Gentile M; Petraroli A; Balestrieri B; Marone G
    Eur J Immunol; 2002 Jan; 32(1):67-76. PubMed ID: 11754005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secretory phospholipase A2 cleavage of intravasated bone marrow primes human neutrophils.
    Gago LA; Moore EE; Partrick DA; Sauaia A; Davis CM; Toal TR; Silliman CC
    J Trauma; 1998 Apr; 44(4):660-4. PubMed ID: 9555838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyunsaturated fatty acids potentiate interleukin-1-stimulated arachidonic acid release by cells overexpressing type IIA secretory phospholipase A2.
    Kambe T; Murakami M; Kudo I
    FEBS Lett; 1999 Jun; 453(1-2):81-4. PubMed ID: 10403380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of dexamethasone and transforming growth factor-beta 2 on group II phospholipase A2 mRNA and activity levels in interleukin 1 beta- and forskolin-stimulated mesangial cells.
    Vervoordeldonk MJ; Schalkwijk CG; Pfeilschifter J; van den Bosch H
    Biochem J; 1996 Apr; 315 ( Pt 2)(Pt 2):435-41. PubMed ID: 8615811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
    Stam TC; Swaak AJ; Kruit WH; Stoter G; Eggermont AM
    Eur J Clin Invest; 2000 Apr; 30(4):336-43. PubMed ID: 10759883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: role of neutrophil interleukin-8 release.
    Zentay Z; Sharaf M; Qadir M; Drafta D; Davidson D
    Pediatr Res; 1999 Oct; 46(4):406-10. PubMed ID: 10509360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-hemorrhagic shock mesenteric lymph lipids prime neutrophils for enhanced cytotoxicity via phospholipase A2.
    Gonzalez RJ; Moore EE; Ciesla DJ; Meng X; Biffl WL; Silliman CC
    Shock; 2001 Sep; 16(3):218-22. PubMed ID: 11531024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
    Snyder DW; Bach NJ; Dillard RD; Draheim SE; Carlson DG; Fox N; Roehm NW; Armstrong CT; Chang CH; Hartley LW; Johnson LM; Roman CR; Smith AC; Song M; Fleisch JH
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1117-24. PubMed ID: 10027849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes.
    Pruzanski W; Bogoch E; Katz A; Wloch M; Stefanski E; Grouix B; Sakotic G; Vadas P
    J Rheumatol; 1995 Nov; 22(11):2114-9. PubMed ID: 8596153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.